Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) Net Margin (2022 - 2025)

Dianthus Therapeutics (DNTH) has 4 years of Net Margin data on record, last reported at 10313.13% in Q3 2025.

  • For Q3 2025, Net Margin fell 914117.0% year-over-year to 10313.13%; the TTM value through Sep 2025 reached 1637.34%, down 37988.0%, while the annual FY2024 figure was 1355.24%, 18086.0% up from the prior year.
  • Net Margin reached 10313.13% in Q3 2025 per DNTH's latest filing, up from 16902.59% in the prior quarter.
  • Across five years, Net Margin topped out at 447.89% in Q4 2024 and bottomed at 16902.59% in Q2 2025.
  • Average Net Margin over 4 years is 3442.87%, with a median of 1486.99% recorded in 2023.
  • Peak YoY movement for Net Margin: soared 201971bps in 2024, then crashed -1596346bps in 2025.
  • A 4-year view of Net Margin shows it stood at 868.13% in 2022, then tumbled by -184bps to 2467.61% in 2023, then skyrocketed by 82bps to 447.89% in 2024, then tumbled by -2203bps to 10313.13% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 10313.13% in Q3 2025, 16902.59% in Q2 2025, and 2526.74% in Q1 2025.